Jade Biosciences is a clinical-stage biotech developing monoclonal antibody therapies for autoimmune diseases. Its lead candidate, JADE101, inhibits the cytokine APRIL and is being studied for immunoglobulin A nephropathy (IgAN), a chronic kidney disease; earlier programs include an anti-BAFF-R antibody and other undisclosed antibodies. The company aims at disease-modifying biologics for patients with serious autoimmune and renal conditions.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -32.1 | — |
| Q3 2025 | 0 | — | -25.2 | — |
| Q4 2025 | 0 | — | -31.9 | — |
| Q1 2026 | 0 | — | -40.4 | — |
| Q2 2026 | 0 | — | -55.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Prospect Capital Corporation (PSEC), Cryoport, Inc. (CYRX), Bloomin' Brands, Inc. (BLMN), Great Southern Bancorp, Inc. (GSBC), Rigel Pharmaceuticals, Inc. (RIGL), Rapid7, Inc. (RPD)